BACKGROUND: Despite the results of combined chemoradiation therapy for anal canal squamous cell carcinoma (SCC), up to 30 % of patients will undergo abdominoperineal resection (APR). The aim of this study was to evaluate oncologic outcomes, survival, and recurrence, following APR for anal canal SCC performed in a single center over a 13-year period. METHODS: All patients who underwent APR for anal canal SCC between 1996 and 2009 were retrospectively included. Demographic data, details on treatments, pathological report, and follow-up were noted. Survival curves were plotted using the Kaplan-Meier method and potential prognostic factors were evaluated using Cox proportional hazards models. RESULTS: A total of 105 patients (77 women) were included. Indications for APR included tumor persistence (n = 42; 40 %), recurrence (n = 55; 52.4 %), or a contraindication to radiotherapy (n = 8; 7.6 %). Median follow-up was 33.3 months (range, 1.5-174.3 months). Overall survival and disease-free survival were, respectively, 61 and 48 % at 5 years. In multivariate analysis, tumor stage (T3 or T4), positive margin on pathologic examination and existence of distant metastases at the time of the surgery were associated with a poor prognosis. The indication for APR (persistent vs recurrent disease), gender, concurrent HIV infection, or performance of a VRAM flap did not influence OS or DFS. Overall recurrence rate was 42.6 % (n = 43 of 101). The type of recurrence did not exert a significant effect on survival (p = .4571). CONCLUSION: This study describes the largest single series of APR for anal carcinoma. Major prognostic factors for survival and recurrence were T status and involved margin. The 5-year overall survival was 60 %.
BACKGROUND: Despite the results of combined chemoradiation therapy for anal canal squamous cell carcinoma (SCC), up to 30 % of patients will undergo abdominoperineal resection (APR). The aim of this study was to evaluate oncologic outcomes, survival, and recurrence, following APR for anal canal SCC performed in a single center over a 13-year period. METHODS: All patients who underwent APR for anal canal SCC between 1996 and 2009 were retrospectively included. Demographic data, details on treatments, pathological report, and follow-up were noted. Survival curves were plotted using the Kaplan-Meier method and potential prognostic factors were evaluated using Cox proportional hazards models. RESULTS: A total of 105 patients (77 women) were included. Indications for APR included tumor persistence (n = 42; 40 %), recurrence (n = 55; 52.4 %), or a contraindication to radiotherapy (n = 8; 7.6 %). Median follow-up was 33.3 months (range, 1.5-174.3 months). Overall survival and disease-free survival were, respectively, 61 and 48 % at 5 years. In multivariate analysis, tumor stage (T3 or T4), positive margin on pathologic examination and existence of distant metastases at the time of the surgery were associated with a poor prognosis. The indication for APR (persistent vs recurrent disease), gender, concurrent HIV infection, or performance of a VRAM flap did not influence OS or DFS. Overall recurrence rate was 42.6 % (n = 43 of 101). The type of recurrence did not exert a significant effect on survival (p = .4571). CONCLUSION: This study describes the largest single series of APR for anal carcinoma. Major prognostic factors for survival and recurrence were T status and involved margin. The 5-year overall survival was 60 %.
Authors: Dimitrios Raptis; Ignaz Schneider; Klaus E Matzel; Oliver Ott; Rainer Fietkau; Werner Hohenberger Journal: Dtsch Arztebl Int Date: 2015-04-03 Impact factor: 5.594
Authors: Ira L Leeds; Hasan Alturki; Joseph K Canner; Eric B Schneider; Jonathan E Efron; Elizabeth C Wick; Susan L Gearhart; Bashar Safar; Sandy H Fang Journal: World J Surg Oncol Date: 2016-08-05 Impact factor: 2.754
Authors: Rohit Kochhar; Andrew G Renehan; Damian Mullan; Bipasha Chakrabarty; Mark P Saunders; Bernadette M Carrington Journal: Eur Radiol Date: 2016-04-18 Impact factor: 5.315
Authors: J A W Hagemans; S E Blinde; J J Nuyttens; W G Morshuis; M A M Mureau; J Rothbarth; C Verhoef; J W A Burger Journal: Ann Surg Oncol Date: 2018-04-24 Impact factor: 5.344
Authors: Jen Y Lee; Rosalind J Cutts; Ingrid White; Yolanda Augustin; Isaac Garcia-Murillas; Kerry Fenwick; Nik Matthews; Nicholas C Turner; Kevin Harrington; Duncan C Gilbert; Shreerang Bhide Journal: Front Oncol Date: 2020-04-17 Impact factor: 5.738